surmount-1 trial tirzepatide weight loss non-diabetic for the Maintenance of Body Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity surmount-1 trial tirzepatide weight loss
Description
What we know (and dont know) about GLP-1 drugs, fertility, and birth control
Semaglutide eligibility goes beyond BMI alone
On March 20, 2023, the patent for semaglutide expired in India, bringing nearly 40 affordable generics to market
At the ESC Congress 2025, NovoNordisk revealed realworld data showing Wegovy (semaglutide 2.4mg) reduces major adverse cardiovascular events by 57% compared with tirzepatide in overweight/obese patients with established CVD and no diabetes.
Does Mounjaro stop working over time
"The effect of oral alpha-galactosidase on intestinal gas production and gas-related symptoms."Digestive Diseases and Sciences
